Description: Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Home Page: palatin.com
PTN Technical Analysis
Cedar Brook Corporate Center
Cranbury,
NJ
08512
United States
Phone:
609 495 2200
Officers
| Name | Title |
|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, Pres, CEO & Director |
| Mr. Stephen T. Wills CPA, CPA, MST | CFO, COO, Exec. VP, Treasurer & Sec. |
| Burns McClellan | VP of Investor Relations |
| Mr. Stephen A. Slusher Esq. | Chief Legal Officer |
| Dr. Michael B. Raizman M.D. | Chief Medical Officer |
| Mr. James E. Hattersley | Sr. VP of Bus. Devel. |
| Mr. John Dodd Ph.D. | Sr. VP of Preclinical Devel. |
| Mr. Robert Jordan | Sr. VP of Program Operations |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.2522 |
| Price-to-Sales TTM: | 15.6832 |
| IPO Date: | 1993-10-28 |
| Fiscal Year End: | June |
| Full Time Employees: | 33 |